HEP 689

Drug Profile

HEP 689

Alternative Names: SB 235699

Latest Information Update: 03 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Imidazoles; Small molecules
  • Mechanism of Action Cytokine inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 03 Nov 2000 Discontinued-I for Psoriasis in Europe (Unknown route)
  • 09 Nov 1999 Preclinical studies have been added to the pharmacodynamics section
  • 21 Jul 1999 Phase-I clinical trials for Psoriasis in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top